Joost Raaphorst

List of Publications by Year
in descending order

58	1,817	331670 21	289244 40
papers	citations	h-index	g-index

60	60	60	2268
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	N-of-1 Trials in Neurology. Neurology, 2022, 98, .	1.1	7
2	Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis. Autoimmunity Reviews, 2022, 21, 102997.	5.8	18
3	Cortical and subcortical changes in resting-state neuronal activity and connectivity in early symptomatic ALS and advanced frontotemporal dementia. NeuroImage: Clinical, 2022, 34, 102965.	2.7	3
4	Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. BMC Medicine, 2022, 20, 100.	5.5	15
5	Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatology, The, 2022, 4, e338-e350.	3.9	88
6	Assessment of disability in idiopathic inflammatory myopathy: a call for linearity. Rheumatology, 2022, 61, 3420-3426.	1.9	1
7	Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review. International Journal of Molecular Sciences, 2022, 23, 4301.	4.1	16
8	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatology, The, 2022, 4, e417-e429.	3.9	33
9	Ultrasound and MR muscle imaging in new onset idiopathic inflammatory myopathies at diagnosis and after treatment: a comparative pilot study. Rheumatology, 2022, 62, 300-309.	1.9	6
10	Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology, 2021, 60, 1784-1792.	1.9	25
11	New Insights in Adherence and Survival in Myotonic Dystrophy Patients Using Home Mechanical Ventilation. Respiration, 2021, 100, 154-163.	2.6	6
12	Screening for cognition in amyotrophic lateral sclerosis: test characteristics of a new screen. Journal of Neurology, 2021, 268, 2533-2540.	3.6	4
13	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.7	14
14	Human brain pathology in myotonic dystrophy type 1: A systematic review. Neuropathology, 2021, 41, 3-20.	1.2	21
15	Intramuscular adipose tissue at level Th12 is associated with survival in COVIDâ€19. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 823-827.	7.3	15
16	N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, jnnp-2021-326347.	1.9	1
17	Behavioural Impairment and Frontotemporal Dementia in Oculopharyngeal Muscular Dystrophy. Journal of Neuromuscular Diseases, 2021, , 1-7.	2.6	1
18	A visual brain-computer interface as communication aid for patients with amyotrophic lateral sclerosis. Clinical Neurophysiology, 2021, 132, 2404-2415.	1.5	17

#	Article	IF	Citations
19	OptimisAtion of Diagnostic Accuracy in idioPathic inflammaTory myopathies (ADAPT study): a protocol for a prospective diagnostic accuracy study of multimodality testing in patients suspected of a treatable idiopathic inflammatory myopathy. BMJ Open, 2021, 11, e053594.	1.9	1
20	Meet and eat, an interdisciplinary group intervention for patients with myotonic dystrophy about healthy nutrition, meal preparation, and consumption: a feasibility study. Disability and Rehabilitation, 2020, 42, 1561-1568.	1.8	2
21	Comment on â€œSystematic retrospective study on 64 patients anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancyâ€. Journal of the American Academy of Dermatology, 2020, 83, e459-e460.	1.2	3
22	De Novo and Bi-allelic Pathogenic Variants in NARS1 Cause Neurodevelopmental Delay Due to Toxic Gain-of-Function and Partial Loss-of-Function Effects. American Journal of Human Genetics, 2020, 107, 311-324.	6.2	32
23	Characterization of EEG-based functional brain networks in myotonic dystrophy type 1. Clinical Neurophysiology, 2020, 131, 1886-1895.	1.5	1
24	Cognitive and behavioral status in Japanese ALS patients: a multicenter study. Journal of Neurology, 2020, 267, 1321-1330.	3.6	12
25	High incidence of falls in patients with myotonic dystrophy type 1 and 2: A prospective study. Neuromuscular Disorders, 2019, 29, 758-765.	0.6	10
26	Response to: Diagnostic value of additional histopathological fascia examination in idiopathic inflammatory myopathies. European Journal of Neurology, 2019, 26, e95.	3.3	0
27	Diagnostic value of additional histopathological fascia examination in idiopathic inflammatory myopathies. European Journal of Neurology, 2019, 26, 1494-1496.	3.3	3
28	White matter changes in the perforant path area in patients with amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 2019, 45, 570-585.	3.2	22
29	Affective symptoms and apathy in myotonic dystrophy type 1 a systematic review and meta-analysis. Journal of Affective Disorders, 2019, 250, 260-269.	4.1	23
30	Reader response: ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology, 2019, 93, 85.2-86.	1.1	1
31	Response to the letter to editor about â€œAffective symptoms and apathy in myotonic dystrophy type 1 a systematic review and meta-analysisâ€. Journal of Affective Disorders, 2019, 259, 468-470.	4.1	0
32	Structural white matter networks in myotonic dystrophy type 1. NeuroImage: Clinical, 2019, 21, 101615.	2.7	23
33	The cognitive profile of behavioural variant FTD and its similarities with ALS: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 995-1002.	1.9	47
34	Falls and resulting fractures in Myotonic Dystrophy: Results from a multinational retrospective survey. Neuromuscular Disorders, 2018, 28, 229-235.	0.6	19
35	Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands. Neuromuscular Disorders, 2018, 28, 402-407.	0.6	40
36	Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. JAMA - Journal of the American Medical Association, 2018, 320, 2344.	7.4	81

#	Article	IF	Citations
37	Experiences with bariatric surgery in patients with facioscapulohumeral dystrophy and myotonic dystrophy type 1: A qualitative study. Neuromuscular Disorders, 2018, 28, 938-946.	0.6	5
38	Respiratory Assessment of ALS Patients: A Nationwide Survey of Current Dutch Practice. Journal of Neuromuscular Diseases, 2018, 5, 431-438.	2.6	6
39	Respiratory Assessment of ALS Patients: A Nationwide Survey of Current Dutch Practice. Journal of Neuromuscular Diseases, 2018, , 1-8.	2.6	1
40	No association between gluten sensitivity and amyotrophic lateral sclerosis. Journal of Neurology, 2017, 264, 694-700.	3.6	4
41	Exploring the fitness hypothesis in ALS: a population-based case-control study of parental cause of death and lifespan. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 550-556.	1.9	14
42	A case series of PLS patients with frontotemporal dementia and overview of the literature. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 534-548.	1.7	31
43	Brain imaging in myotonic dystrophy type 1. Neurology, 2017, 89, 960-969.	1.1	76
44	The cognitive profile of myotonic dystrophy type 1:ÂA systematic review and meta-analysis. Cortex, 2017, 95, 143-155.	2.4	82
45	The predictive value of respiratory function tests for non-invasive ventilation in amyotrophic lateral sclerosis. Respiratory Research, 2017, 18, 144.	3.6	54
46	Long-Term Air Pollution Exposure and Amyotrophic Lateral Sclerosis in Netherlands: A Population-based Caseâ€“control Study. Environmental Health Perspectives, 2017, 125, 097023.	6.0	54
47	Prevalence of brain and spinal cord inclusions, including dipeptide repeat proteins, in patients with the <scp>C</scp>9<scp>ORF</scp>72 hexanucleotide repeat expansion: a systematic neuropathological review. Neuropathology and Applied Neurobiology, 2016, 42, 547-560.	3.2	34
48	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. Journal of Alzheimer's Disease, 2016, 55, 585-595.	2.6	41
49	Japanese version of the ALS-FTD-Questionnaire (ALS-FTD-Q-J). Journal of the Neurological Sciences, 2016, 367, 51-55.	0.6	9
50	The frontotemporal syndrome of ALS is associated with poor survival. Journal of Neurology, 2016, 263, 2476-2483.	3.6	46
51	The cognitive profile of ALS: a systematic review and meta-analysis update. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 611-619.	1.9	232
52	<scp>RYR</scp>1â€related myopathies: a wide spectrum of phenotypes throughout life. European Journal of Neurology, 2015, 22, 1094-1112.	3.3	111
53	Prose memory impairment in amyotrophic lateral sclerosis patients is related to hippocampus volume. European Journal of Neurology, 2015, 22, 547-554.	3.3	45
54	Prefrontal involvement related to cognitive impairment in progressive muscular atrophy. Neurology, 2014, 83, 818-825.	1.1	22

#	Article	IF	Citations
55	Treatment of respiratory impairment in patients with motor neuron disease in the <scp>N</scp>etherlands: patient preference and timing of referral. European Journal of Neurology, 2013, 20, 1524-1530.	3.3	14
56	A systematic review of behavioural changes in motor neuron disease. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 493-501.	2.1	118
57	The ALS-FTD-Q. Neurology, 2012, 79, 1377-1383.	1.1	91
58	The cognitive profile of amyotrophic lateral sclerosis: A meta-analysis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 27-37.	2.1	116